ClinicalTrials.gg
RecruitingNCT06793956Updated Mar 13, 2025

Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma

A Phase 1 interventional study of Sintilimab and Linperlisib Combination Treatment in Extranodal Natural Killer/T Cell Lymphoma, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by Sun Yat-sen University · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Lymphoma, T-Cell by Sun Yat-sen University — 6 open to participants now, 8 under way, 1 of them phase 3. Lymphoma, T-Cell · Sun Yat-sen University.

Started
2025
the only one that year
Phase 1
Only one
of the 11
Registered
9th of 11
by date

Among the 11 studies in Lymphoma, T-Cell by Sun Yat-sen University, this one is the only one that started in 2025, is the only one in phase 1, and was the 9th registered.

Lymphoma, T-Cell

310 studies on the registry are indexed under Lymphoma, T-Cell; 76 are open to participants now.

Browse Lymphoma, T-Cell studies →

Open to participants now

6 of the 11 studies in Lymphoma, T-Cell by Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 66 Lymphoma, T-Cell studies recruiting now, 40 (61%) set no upper age limit and 20 (30%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Lymphoma, T-Cell by Sun Yat-sen University, or all of them as a file.
02

Study summary

This is an open-label, phase Ib study evaluating the combination treatment of sintilimab and linperlisib in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (NKTCL).

03

Conditions studied

  • Extranodal Natural Killer/T Cell Lymphoma

Browse trials for

Keywords

  • Sintilimab
  • Linperlisib
  • Extranodal Natural Killer/T Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. confirmed extranodal NKTCL.
  2. Voluntary participation in the clinical study; fully understand the study, and have signed the written form.
  3. Age ≥ 18 years.
  4. NKTCL after failure of at least one line of asparaginase-based chemotherapy or chemoradiotherapy regimen.
  5. performance status: 0-2.
  6. Estimated survival time ≥ 3 months.
  7. At least one according to the Lugano 2014 lymphoma evaluation criteria.
  8. Adequate organ and bone marrow function.

Key Exclusion Criteria:

  1. Patients previously treated with PI3K inhibitors.
  2. Patients with hemophagocytic syndrome.
  3. Patients known to be allergic to any component of monoclonal antibodies.
  4. Patients with a history of other within the past 5 years or concurrent malignancies (excluding basal cell carcinoma of the skin).
  5. Patients with aggressive NK-cell leukemia or central nervous system involvement.
  6. Patients who have participated in other drug clinical trials within 4 weeks prior to the start of this study or have received anti-tumor treatment within 4 weeks before the study initiation.
  7. Patients with gastrointestinal abnormalities that may affect drug intake, transport, or absorption (e.g., inability to swallow, chronic diarrhea, intestinal obstruction) or patients who have undergone total gastrectomy.
  8. Patients with a history of interstitial lung disease (except for asymptomatic interstitial lung disease caused by radiotherapy).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Sintilimab and Linperlisib Combination Treatment

    Drug: Sintilimab and Linperlisib Combination Treatment

Interventions

  • DrugSintilimab and Linperlisib Combination Treatment

    Sintilimab administered via intravenous infusion; Linperlisib administered orally.

06

What researchers measure

Primary outcomes

  1. DLT

    Dose-limiting toxicity

    Time frame: Cycle 1 (21 days)

  2. RP2D

    Phase II Recommended Dose

    Time frame: Cycle 1 (21 days)

Secondary outcomes

  1. Objective response rate (ORR)

    To investigate the antitumor efficacy

    Time frame: Up to 24 weeks

  2. AE and SAE

    Number of participants with adverse events (AE) and severe adverse events (SAE)

    Time frame: Up to 24 weeks

  3. 2-year Progression-free survival(PFS)

    To investigate the antitumor efficacy

    Time frame: Defined as the proportion of patients without disease progresion, treatment discontinuation, or death for any reason within 24 months of enrollment

  4. 2-year Overall survival(OS)

    To investigate the antitumor efficacy

    Time frame: Defined as the proportion of patients without disease progresion, treatment discontinuation, or death for any reason within 24 months of enrollment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jan 2026, 11 months after the start.

Of 40 non-industry phase 1 interventional studies under Lymphoma, T-Cell, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 11 months is below that.

Counting every sponsor, half of 59 studies reached it within 57 months; a quarter within 26 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2025
First posted
Jan 27, 2025
StartActual
Feb 21, 2025
Primary completionEst.
Jan 31, 2026
CompletionEst.
Jan 31, 2030
Last update
Mar 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06793956
Responsible party
Qingqing Cai (Professor, Sun Yat-sen University) — Principal investigator
First posted
Jan 27, 2025
Start date
Feb 21, 2025
Primary completion
Jan 31, 2026 (estimated)
Completion
Jan 31, 2030 (estimated)
Last update
Mar 13, 2025

Study contacts

Qingqing Cai, MD. PhD.
Contact
caiqq@sysucc.org.cn
0086-20-87342823

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion